VVUS
Vivus Announces Positive Phase 3 Clinical Trial Results for Evamist (VVUS) 3.15 : Co announces positive results from the pivotal Phase 3 clinical trial of Evamist. Vivus' investigational estradiol metered dose transdermal spray is being developed for the treatment of vasomotor symptoms associated with menopause. The study showed a statistically significant reduction in the number and severity of moderate and severe hot flashes for all three doses tested. Co says it plans to file an N.D.A. for Evamist in the second half of 2006
2- CROX
Crocs beats by 3 cents; issues upside guidance (CROX) 32.35 +0.85: Reports Q1 (Mar) earnings of $0.17 per share (including share-based compensation), $0.03 better than the Reuters Estimates consensus of $0.14; revenues rose 307.3% year/year to $44.8 mln vs the $36.2 mln consensus. Co issues upside guidance for Q2, sees EPS of $0.21-0.22 vs. $0.19 consensus; sees Q2 revs of $53-55 mln vs. $45.39 mln consensus. Co issues upside guidance for FY06, sees EPS of $0.77-0.79 vs. $0.70 consensus; sees FY06 revs of $200-205 mln vs. $176.47 mln consensus
Piper Jaffray raises their CROX tgt to $38
الجزء الثاني ل EXPD اليوم
Vivus Announces Positive Phase 3 Clinical Trial Results for Evamist (VVUS) 3.15 : Co announces positive results from the pivotal Phase 3 clinical trial of Evamist. Vivus' investigational estradiol metered dose transdermal spray is being developed for the treatment of vasomotor symptoms associated with menopause. The study showed a statistically significant reduction in the number and severity of moderate and severe hot flashes for all three doses tested. Co says it plans to file an N.D.A. for Evamist in the second half of 2006
2- CROX
Crocs beats by 3 cents; issues upside guidance (CROX) 32.35 +0.85: Reports Q1 (Mar) earnings of $0.17 per share (including share-based compensation), $0.03 better than the Reuters Estimates consensus of $0.14; revenues rose 307.3% year/year to $44.8 mln vs the $36.2 mln consensus. Co issues upside guidance for Q2, sees EPS of $0.21-0.22 vs. $0.19 consensus; sees Q2 revs of $53-55 mln vs. $45.39 mln consensus. Co issues upside guidance for FY06, sees EPS of $0.77-0.79 vs. $0.70 consensus; sees FY06 revs of $200-205 mln vs. $176.47 mln consensus
Piper Jaffray raises their CROX tgt to $38
الجزء الثاني ل EXPD اليوم